## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM 8-K

# CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 13, 2021

# ARTELO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada	333-199213	33-1220924
(State or other jurisdiction	(Commission	\ 1 \ \ 1
of incorporation)	File Number	Identification No.)
505 Lomas Santa Fe, Suite 160		
Solana Beach, CA USA		92075
(Address of principal executive offices	s)	(Zip Code)
Registrant's tele	ephone number, includin	g area code <b>760-943-1689</b>
	ct Street, Suite 210, La	
(Former name	e or former address, if ch	anged since last report.)
Check the appropriate box below if the Form 8-K filing following provisions:	is intended to simultane	ously satisfy the filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under th	e Securities Act (17 CFF	2 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the E	Exchange Act (17 CFR 24	40.14a-12)
☐ Pre-commencement communications pursuant to Rule	14d-2(b) under the Exch	ange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule	13e-4(c) under the Excha	ange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ARTL	The Nasdaq Stock Market, LLC
Warrants	ARTLW	The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emergin Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR		fined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or growth company $\Box$
If an emerging growth company, indicate by check mark if or revised financial accounting standards provided pursuant		not to use the extended transition period for complying with any new exchange Act. $\square$

#### Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 13, 2021, the board of directors (the "Board") of Artelo Biosciences, Inc. (the "Company") amended Section 1.7 of the Company's Bylaws, effective immediately (the "Bylaws Amendment"). The Bylaws were amended to update the definition of a quorum of shareholders at a meeting to 45%.

The Bylaws Amendment is filed as Exhibit 3.1 hereto and are incorporated herein by reference.

### Item 9.01. Financial Statements and Exhibits.

#### (d) Exhibits.

Exhibit No.	Description
3.1_	Bylaws Amendment.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### ARTELO BIOSCIENCES, INC.

/s/ Gregory D. Gorgas

Gregory D. Gorgas President & Chief Executive Officer

Date: July 14, 2021

#### AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC.

The Bylaws (the "Bylaws") of Artelo Biosciences, Inc. (the "Company"), adopted by the Board of Directors of the Company (the "Board") are hereby amended (the "Amendment") as follows:

1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows:

"The presence in person or by proxy of the holders of at least 45% of the votes entitled to be cast on a matter at a meeting shall constitute a quorum of shareholders for that matter."

Except as expressly modified hereby, the Bylaws and all of the provisions contained therein shall remain in full force and effect. The Amendment and the Bylaws shall be read and construed together as a single instrument. To the extent of any inconsistency between the terms contained in the Bylaws and the Amendment, the terms of the Amendment shall control. Any reference in any document or agreement to the Bylaws shall include the Amendment and shall refer to the Bylaws as amended by the Amendment.

\* \* \*